Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
3 clinical trials · Sponsor
◉ Watch Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors (NCT07517198) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 2026-04-13 |
| Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies (NCT06980116) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 2025-03-31 |
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (NCT05985655) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 2023-07-06 |
Track Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.